2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Behavioral Addiction

Behavioral Addiction

Addictive behaviors encompass a range of disorders characterized by impaired control over substance use or compulsive engagement in rewarding activities despite harm, including drug dependence, compulsive overeating, gambling, and shopping. These behaviors are classified as chronic, relapsing brain disorders influenced by genetic, psychosocial, and environmental factors, with diagnostic criteria outlined in the DSM-5. Neurobiological evidence demonstrates that excessive consumption of food or engagement in behavioral addictions induces similar neuroadaptations in the brain's reward circuitry as drug abuse, implicating shared neural mechanisms. Imaging studies consistently reveal disrupted reward system function across various addictive behaviors, supporting their classification under a unified model of addiction. As such, addictive behaviors represent significant public health challenges due to their persistent, relapsing nature and severe health consequences.

Behavioral Addiction (10):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135783
    AT 1001 1314801-63-2 99.94%
    AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease.
    AT 1001
  • HY-136832
    Noribogaine hydrochloride 110514-35-7 99.9%
    Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity.
    Noribogaine hydrochloride
  • HY-167856
    RTI-122 3034664-39-3
    RTI-122 is a selective, blood-brain barrier-permeable GPR88 agonist (cAMP EC50=11 nM), with EC50 values of 11.5 nM and 155 nM for human and mouse GPR88, respectively ([35S]GTPγS assay). By activating the GPR88 receptor to regulate the cAMP signaling pathway and G protein activity, RTI-122 significantly attenuates Binge-like drinking, reduces alcohol intake, and decreases alcohol-seeking motivation. RTI-122 blocks the reinstatement of alcohol-seeking behavior without affecting water or sucrose intake. RTI-122 exhibits metabolic stability in mice (T1/2=5.8 h) and can be used to investigate alcohol use disorder.
    RTI-122
  • HY-N0927
    (-)-Isocorypalmine 483-34-1 99.67%
    (-)-Isocorypalmine (Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine) is a dopamine receptor ligand and modulator capable of crossing the blood-brain barrier. (-)-Isocorypalmine exhibits receptor selectivity, acting as a partial agonist of dopamine D1 and D5 receptors (coupled via Gs proteins), as well as an antagonist of D2, D3 and D4 receptors (by blocking Gi protein-mediated signaling). (-)-Isocorypalmine shows no significant binding to various non-dopamine receptors, ion channels and transporters. (-)-Isocorypalmine is metabolically stable in vivo, effectively inhibits spontaneous and cocaine-induced hyperlocomotion, sensitization and conditioned place preference in mice, and does not induce addictive place preference when administered alone. (-)-Isocorypalmine can be used in addiction research.
    (-)-Isocorypalmine
  • HY-125790
    Cyclazocine 3572-80-3
    Cyclazocine is a μ, δ, and κ opioid receptor modulator with Ki values of 0.32, 1.1, and 0.18 nM, respectively. Cyclazocine exhibits "mixed" pharmacological activities, acting as a μ-partial antagonist, κ-agonist, and low-affinity δ ligand. Cyclazocine shows antinociceptive activity in mice. Cyclazocine can be used in studies on psychoactive substance addiction.
    Cyclazocine
  • HY-W609889
    5-HT2A receptor agonist-14 1239879-65-2
    5-HT2A receptor agonist-14 (Compound I-23) is a tricyclic 5-HT2A receptor agonist with a pEC50 value ≥ 6. 5-HT2A receptor agonist-14 can be used in research related to depression, anxiety, substance abuse and headache.
    5-HT2A receptor agonist-14
  • HY-123889
    VK4-116 1982347-43-2
    VK4-116 (Compound 19) is a selective Dopamine D3 receptor (D3R) antagonist with a Ki of 6.84 nM.VK4-116 significantly inhibits Oxycodone-induced hyperlocomotion and locomotor sensitization in mouse models. VK4-116 with pretreatment also inhibits the acquisition of Oxycodone-induced conditioned place preference (CPP) in rat models.
    VK4-116
  • HY-124186
    LR1143 150151-15-8
    LR1143 is a dopamine transporter (DAT) and 5-HT uptake inhibitor, with IC50 values of 3.4 nM and 112 nM in rats, respectively. LR1143 binds to DAT labeled with the dopamine reuptake inhibitor GBR 12935 (HY-12242A), with an IC50 of 4.4 nM. LR1143 shows lower selectivity for DAT than for serotonin reuptake sites. LR1143 can be used in studies related to cocaine abuse.
    LR1143
  • HY-124907
    AI 3-25755 328-04-1
    AI 3-25755 (OMS-403) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. AI 3-25755 can be used for research on opioid abuse and smoking cessation.
    AI 3-25755
  • HY-18101
    BD-1063 150208-28-9
    BD-1063 is a selective σ-1 receptor antagonist with inhibitory activity against TRPC5 and TRPM3. BD-1063 exerts anti-hyperalgesic and anti-allodynic effects by inhibiting sustained calcium influx mediated by TRPC5 and TRPM3, and reverses the effects of Carrageenan (HY-125474). BD-1063 also significantly reduces excessive ethanol self-administration behavior. BD-1063 is widely used in studies on the mechanisms underlying neuropathic pain, inflammatory hyperalgesia, and alcohol abuse and dependence.
    BD-1063